tiprankstipranks

Analyst Profile

Followed by 949 followers
.
Matthew Harrison

Matthew Harrison

Morgan Stanley
Wall Street Analyst
#727 out of 7,963 Wall Street Analysts
#1,408 out of 22,261 experts

Success Rate

49%
219 out of 443 transactions made a profit

Average Return

+6.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Matthew Harrison's trades since 2012 and holding each position for 1 Year would result in 49.44% of your transactions generating a profit, with an average return of 6.3% per rating.

Stock Rating Distribution

990Ratings
48.69% Buy
45.45% Hold
5.86% Sell
Distribution of Matthew Harrison's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Moderna
(MRNA)
Rating:Buy
Date:Aug 09, 2019 - Aug 09, 2020
Return:+455.80%
The most profitable rating made by Matthew Harrison

Matthew Harrison's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
RDEA
Ardea Biosciences
Apr 12, 2012
Buy
Initiated
1Ratings
0.00%
~ACHN
Achillion Pharmaceuticals
Apr 19, 2012
Sell
Downgraded
1Ratings
0.00%
ITMN
InterMune
Aug 15, 2012
Hold
Reiterated
4Ratings
0.00%
PCYC
Pharmacyclics
Nov 05, 2014
Hold
Initiated
5Ratings
0.00%
Bausch Health Companies
Oct 02, 2015
Hold
Downgraded
$200.00
(2777.70% Upside)
1Ratings
0.00%
Syndax Pharmaceuticals
Jul 18, 2016
Buy
Reiterated
4Ratings
67%
-0.40%
Chimerix
Jul 18, 2016
Sell
Reiterated
5Ratings
50%
-13.95%
Infinity Pharma
Aug 11, 2016
Hold
Reiterated
$1.00
(-15.97% Downside)
7Ratings
0.00%
Ironwood Pharma
Aug 26, 2016
Hold
Reiterated
$12.00
(15.72% Upside)
4Ratings
0.00%
IVERIC bio
Dec 13, 2016
Hold
Downgraded
3Ratings
0%
-91.20%
List of latest recommendations made by Matthew Harrison. Click to expand and see Matthew Harrison's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >